NCT05282082: SAMPAN

Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.

Completed Last updated 10 March 2026

What this trial tests

trial in Pseudomonas Aeruginosa in 2,105 participants. Completed in 30 June 2024.

Timeline

1 March 2022

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Erasmus Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,105
Start date	1 March 2022
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	3 locations across Italy, Netherlands, Indonesia

Conditions studied

• Pseudomonas Aeruginosa — all drugs for Pseudomonas Aeruginosa →
• Colonization, Asymptomatic — all drugs for Colonization, Asymptomatic →
• Nosocomial Infection — all drugs for Nosocomial Infection →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Pseudomonas Aeruginosa or Colonization, Asymptomatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CRPA) makes infections by these pathogens almost untreatable. The World Health Organization now ranks CRPA highest in the list of 'urgent threats'. Information for action to prevent further emergence has to come from insight into sources and transmission routes through smart surveillance. At present, a smart surveillance strategy is not available for CRPA. The aim of this project is to develop a globally-applicable smart surveillance strategy to guide action against the spread of CRPA. Since P. aeruginosa prefers moist niches, we will focus on the human-water interface. First, highly-sensitive methods to detect CRPA in specific environmental and human niches will be developed. Subsequently, CRPA will be collected in three study sites with increasing prevalences of CRPA, increasingly warmer climates, and different water situations: Rotterdam (The Netherlands), Rome (Italy), Jakarta (Indonesia). CRPA will be searched for in a variety of niches in the environment outside and inside the hospital, and in healthy humans and hospitalized patients. Whole genome sequencing will be performed to compare the CRPA from different sources and identify transmission routes. Our project will provide insight into the relative contribution of the different potential reservoirs of CRPA to its spread in different settings which will be used for the development of a globally-applicable surveillance strategy for CRPA to guide preventive actions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Sources and Transmission Routes of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>: Study Design and Methodology of the SAMPAN Study.
   van Veen A, Shahab SN, Rijfkogel A, Voor In 't Holt AF, et al · · 2025 · cited 3× · PMID 39858379 · DOI 10.3390/antibiotics14010094
2. Pseudomonas aeruginosa carriage and associated risk factors in healthy individuals and patients from Rotterdam, Rome, and Jakarta.
   van Veen A, Shahab SN, Rijfkogel A, Vos MC, et al · · 2025 · cited 2× · PMID 40691185 · DOI 10.1038/s41598-025-10175-y